ARA 290
10mg
❄️Lyophilized powder (not reconstituted)
Discount per Quantity
| Quantity | Discount | Price per Unit |
|---|---|---|
| 5 - 10 | 10% | €39.59 |
| 11 - 20 | 15% | €37.39 |
| 21+ | 20% | €35.19 |
Rigorous third-party testing
Every batch of our research chemicals and peptides undergoes independent third-party laboratory testing for purity and identity.
Total: €43.99
ARA 290 is supplied as a catalogued research material in 10 mg.
ARA 290 is the development name for cibinetide, an 11-residue peptide beginning with pyroglutamate. The N-terminal cyclization and exact salt form must be confirmed for the batch before registry data are applied [1,2].
Chemical properties and registry information
| Property | Value |
|---|---|
| Name and synonyms | Cibinetide, Helix B surface peptide, ARA290 |
| Material category | EPO mimetic peptide |
| Sequence | pE-EQLEALNSS-NH2 |
| Molecular formula | C51H87N17O20 |
| Average molecular mass | 1255.38 g/mol |
| CAS Registry Number | 863221-39-2 |
| PubChem CID | CID 56841819 |
| Structural features | 11-amino acid linear peptide derived from erythropoietin (EPO). N-terminal pyroglutamic acid (pGlu). C-terminal amidation. |
| Appearance | White to off-white lyophilised powder |
| Solubility | Soluble in sterile water or bacteriostatic water. |
| Physical form | Catalogue vial; exact salt/counter-ion and excipients are batch-specific and must be verified in the CoA and SDS. |
Registry values apply only to the specific molecular entity, sequence, termini and material form. Batch records take precedence over family-level literature identifiers.
ARA 290 is a non-erythropoietic peptide that selectively activates the innate repair receptor (IRR), a heterocomplex of the EPO receptor and β-common receptor, mediating tissue protection without stimulating red blood cell production.
Research background and published evidence
Published research
Cibinetide has been studied as an erythropoietin-derived investigational peptide in receptor-signaling, tissue-response and early clinical research [2–4].
Current scientific understanding
The available human studies were small and investigational and do not establish approved clinical efficacy. Findings for a study drug or full erythropoietin cannot authenticate or be transferred to this catalogue batch.
Cibinetide remains an investigational peptide; similarity to an erythropoietin-derived sequence does not make it erythropoietin or an authorized medicinal product.
Technical comparison
| Aspect | This catalogue material | Comparator |
|---|---|---|
| Identity | ARA 290/cibinetide 11-residue peptide, subject to batch confirmation | Full-length glycosylated erythropoietin protein |
| Structural distinction | Short synthetic sequence with N-terminal pyroglutamate and no protein glycosylation | Large, folded and glycosylated protein with a distinct molecular identity |
| Analytical implication | Confirm pyroglutamate, sequence, termini, intact mass and counter-ion | Protein-level identity and glycoform methods are not interchangeable with peptide analysis |
Quality and testing
Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot or similarly named material must not be treated as evidence for this product.
Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.
Laboratory handling and storage
Store and handle only under the conditions stated on the product label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination. Do not infer storage, solvent compatibility or stability from a related compound.
Laboratory preparation, analytical-method selection, risk assessment, personal protective equipment and waste disposal should follow the applicable SDS and the institution's approved procedures.
Regulatory and legal status
| Research-use notice | This material is supplied exclusively for laboratory research by qualified professionals and is not intended for human or veterinary use. Purchasers are responsible for compliance with applicable local requirements. |
Sources and references
- [1] PubChem. Cibinetide, CID 91810664.
- [2] American Medical Association. Cibinetide USAN substance record.
- [3] Brines et al. Pilot randomized study of ARA 290. Molecular Medicine (2014).
- [4] Culver et al. Phase 2b investigational study of cibinetide. European Respiratory Journal (2017).
Frequently Asked Questions
Do the CAS number and PubChem CID apply to every batch form?
Only when the exact sequence or structure, termini, conjugation, salt or counter-ion and hydration state match. The batch CoA and SDS govern; a related-compound identifier must not be substituted.
What does an analytical purity result mean?
It is method- and report-specific. For example, an HPLC area percentage is not automatically the same as identity, net content, sterility, endotoxin status or absence of elemental impurities.
How should the material be stored and handled?
Follow the exact label, batch CoA and SDS together with the institution's risk assessment. Use only storage and stability information linked to the exact material form and batch.